Chemokine receptor CCR3 antagonists
OwnerBassam Damajinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to antagonists of chemokine receptor CCR3 and to a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The antagonist is a hexapeptide capable of inhibiting a beta-chemokine from binding to a CCR3 receptor. The method includes administering to a subject a therapeutically effective amount of a hexapeptide antagonist of chemokine receptor CCR3. The hexapeptide antagonist binds between a beta-chemokine and the receptor CC3 preventing a beta-chemokine from binding to the receptor CCR3.
Claims22
A hexapeptide for inhibiting a beta-chemokine from binding to a CCR3 receptor, said hexapeptide having a sequence as set forth in SEQ ID NO:
- 1 or SEQ ID NO:
- 2.
A method of treating a subject affected with a disease associated with aberrant leukocyte recruitment, aberrant leukocyte activation or both, said method comprising administering a therapeutically effective amount of a hexapeptide antagonist of a chemokine receptor CCR3 to said subject, said hexapeptide antagonist binding between a beta-chemokine and the chemokine receptor CCR3 and having a sequence as set forth in SEQ ID NO:
- 1 or SEQ ID NO:
- 2.
A method for inhibiting a beta-chemokine from binding to a chemokine receptor CCR3, said method comprising delivering to a cell having the chemokine receptor CCR3 a hexapeptide having a sequence as set forth in SEQ ID NO:
- 1 or SEQ ID NO:
- 2, said hexapeptide inhibiting the beta-chemokine from binding to the chemokine receptor CCR3.
A method for treating a disease associated with aberrant leukocyte recruitment, aberrant leukocyte activation or both, said method comprising inhibiting a beta-chemokine from binding to a CCR3 receptor by administering the hexapeptide of clam 1 to a subject having said disease.
A method of manufacturing a medicament for treating a disease associated with aberrant leukocyte recruitment, activation or both, said method comprising providing the hexapeptide of clam 1 together with a pharmaceutically acceptable carrier.
A method for inhibiting a beta-chemokine from binding to a chemokine receptor CCR3 said method comprising introducing the hexapeptide of clam 1 to a cell including the chemokine receptor CCR3.
Dependencies are inferred from the claim text.